Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | August 27, 2026 | August 28, 2026 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director · President and Chief Executive | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 27, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,526 |
Ending reported balance
After 2026-08-27 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-27 · Exercise / conversion · Acquired 11,148 · Balance 34,674 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Row 2 · 2026-08-27 · Sale · Disposed 11,148 · Balance 23,526 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-27 · Exercise / conversion · Acquired 27,052 · Balance 50,578 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Row 4 · 2026-08-27 · Sale · Disposed 27,052 · Balance 23,526 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-27 · Exercise / conversion · Disposed 11,148 · Balance 0 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F4: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-27 · Exercise / conversion · Disposed 27,052 · Balance 0 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F4: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F4: The option is fully vested.
Phathom Pharmaceuticals, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2035-02-26 | Direct | 342,500 |
Reported balance
After 2025-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 342,500 · Balance 342,500 F1: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 3,426 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 1,857 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 6,593 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 4,120 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 27,749 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 1
1 source rowRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.30 · Expires 2026-11-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-10 · Disposition to issuer · Disposed 33,846 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.68 · Expires 2027-05-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 11,154 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.14 · Expires 2027-08-17 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.25 · Expires 2028-08-30 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Disposition to issuer · Disposed 5,250 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.
F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 28, 2026 21:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001628280-26-059444 · wk-form4_1787953199.xml · derivative · entry 6 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 11,148 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001628280-26-059444 · wk-form4_1787953199.xml · derivative · entry 5 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,148 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 27,052 | $25.03 | $677,095.33 |
DisclosureSEC source: 0001628280-26-059444 · wk-form4_1787953199.xml · nonDerivative · entry 4 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,526 F3 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 27,052 | $8.63 | $233,458.76 |
DisclosureSEC source: 0001628280-26-059444 · wk-form4_1787953199.xml · nonDerivative · entry 3 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 11,148 | $25.03 | $279,027.75 |
DisclosureSEC source: 0001628280-26-059444 · wk-form4_1787953199.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,526 F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 11,148 | $7.51 | $83,721.48 |
DisclosureSEC source: 0001628280-26-059444 · wk-form4_1787953199.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 1,072 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001628280-26-058648 · wk-form4_1787602781.xml · derivative · entry 3 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,148 Underlying: Common Stock · 1,072 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,072 | $26.04 | $27,912.31 |
DisclosureSEC source: 0001628280-26-058648 · wk-form4_1787602781.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,526 F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,072 | $7.51 | $8,050.72 |
DisclosureSEC source: 0001628280-26-058648 · wk-form4_1787602781.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $21.23 | $0.00 |
DisclosureSEC source: 0001628280-26-042042 · wk-form4_1781054465.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042042 · wk-form4_1781054465.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,526 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 22, 2025, maintained by the Company. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 20,568 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0002065881-25-000025 · wk-form4_1750119440.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 7,609 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000025 · wk-form4_1750119440.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,748 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 16, 2024, maintained by the Company. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:16 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 342,500 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0000950170-25-031048 · ownership.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,500 Underlying: Common Stock · 342,500 shares Expires 2035-02-26 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:19 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 19,109 | $6.59 | $125,884.36 |
DisclosureSEC source: 0000950170-25-008348 · ownership.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,465 F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6503. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,840 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 23:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,687 | $10.85 | $94,238.31 |
DisclosureSEC source: 0001787306-24-000155 · wk-form4_1731541502.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,139 F1 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.7542 to $10.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 18:50 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 33,848 | $11.72 | $396,698.56 |
DisclosureSEC source: 0000950170-24-084179 · ownership.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,734 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · balance_after: Includes 798 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001787306-24-000103 · wk-form4_1718743917.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 10,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000103 · wk-form4_1718743917.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,826 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 20:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 16,851 | $9.11 | $153,512.61 |
DisclosureSEC source: 0000950170-24-036398 · ownership.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,784 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.11 to $9.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 1,604 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024. Read SEC document |
| January 18, 2024 Filed Jan 23, 2024 01:19 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001209191-24-002019 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2034-01-17 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:53 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054346 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,171 F1 · shares: Represents shares earned with respect to performance stock unit awards granted on July 1, 2020 and January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Disposition to issuerStock Option · Derivative | 225,000 | Not disclosed Strike: $39.11 | Not disclosed |
DisclosureSEC source: 0001209191-23-042454 · doc4.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2031-01-27 F1 · price: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Disposition to issuerStock Option · Derivative | 175,000 | Not disclosed Strike: $32.20 | Not disclosed |
DisclosureSEC source: 0001209191-23-042454 · doc4.xml · derivative · entry 3 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2030-06-30 F1 · price: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-042454 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,671 F1 · price: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001787306-23-000058 · wk-form4_1685747445.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000058 · wk-form4_1685747445.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,687 F1 · balance_after: Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 19:19 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 12,919 | $7.82 | $101,025.29 |
DisclosureSEC source: 0001209191-23-023751 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.79 to $7.85. The Reporting Person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 21,096 | Not disclosed Strike: $22.71 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 8 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 21,603 | Not disclosed Strike: $21.47 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 7 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 5,250 | Not disclosed Strike: $7.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 6 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,250 shares Expires 2029-08-22 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $24.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 5 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 22,500 shares Expires 2028-08-30 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $13.14 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 22,500 shares Expires 2027-08-17 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 11,154 | Not disclosed Strike: $12.68 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 3 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,154 shares Expires 2027-05-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 33,846 | Not disclosed Strike: $11.30 | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 33,846 shares Expires 2026-11-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerCommon Shares | 3,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-017716 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2 · shares: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3 · price: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:59 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,436 | $8.54 | $12,265.02 |
DisclosureSEC source: 0001209191-23-016002 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,371 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022. F2 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.53 to $8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2023 Filed Jan 21, 2023 00:39 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 5,821 | $8.20 | $47,729.29 |
DisclosureSEC source: 0001209191-23-004341 · doc4.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,807 F3 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 21, 2023 00:39 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 162,500 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-23-004341 · doc4.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2033-01-18 F4 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| January 19, 2023 Filed Jan 21, 2023 00:39 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 97,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004341 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,628 F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:07 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,526 | $9.60 | $14,649.60 |
DisclosureSEC source: 0001209191-22-058619 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,720 F1 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.59 to $9.90. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 20:45 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 9,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054817 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,859 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person as the annual non-employee director grant. The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time. F2 · shares: Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the "Merger Agreement"). Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048472 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,246 F1 · shares: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,151 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:58 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 11,796 | $0.00 Strike: $20.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012323 · doc1.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Underlying: Common Stock · 11,796 shares Expires 2032-06-01 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:58 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012323 · doc1.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,312 F1 · balance_after: Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 19, 2022 Filed May 20, 2022 21:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031080 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,595 F1 · shares: Represents restricted stock units ("RSUs") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 13, 2022 Filed May 17, 2022 00:45 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 20,500 | $7.41 | $151,835.30 |
DisclosureSEC source: 0001209191-22-029451 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,595 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.28 to $7.56. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 23:47 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 206,250 | $0.00 Strike: $15.21 | $0.00 |
DisclosureSEC source: 0001209191-22-004488 · doc4.xml · derivative · entry 3 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 206,250 shares Expires 2032-01-18 F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 23:47 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 41,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004488 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,095 F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,705 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2021, July 2021 and January 2022. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:40 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 21,096 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-21-063678 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,096 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) November 5, 2022, and (b) the date that is one day prior to the Issuer's 2022 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.